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Cross-reactivity profiles of hybrid capture II,
cobas, and APTIMA human papillomavirus
assays: split-sample study
Sarah Preisler1,2*, Matejka Rebolj3, Ditte Møller Ejegod2, Elsebeth Lynge3, Carsten Rygaard2 and Jesper Bonde1,2
Abstract
Background: High-risk Human Papillomavirus (HPV) testing is replacing cytology in cervical cancer screening as it is
more sensitive for preinvasive cervical lesions. However, the bottleneck of HPV testing is the many false positive test
results (positive tests without cervical lesions). Here, we evaluated to what extent these can be explained by cross-
reactivity, i.e. positive test results without evidence of high-risk HPV genotypes. The patterns of cross-reactivity have
been thoroughly studied for hybrid capture II (HC2) but not yet for newer HPV assays although the manufacturers
claimed no or limited frequency of cross-reactivity. In this independent study we evaluated the frequency of cross-
reactivity for HC2, cobas, and APTIMA assays.
Methods: Consecutive routine cervical screening samples from 5022 Danish women, including 2859 from women
attending primary screening, were tested with the three evaluated DNA and mRNA HPV assays. Genotyping was
undertaken using CLART HPV2 assay, individually detecting 35 genotypes. The presence or absence of cervical
lesions was determined with histological examinations; women with abnormal cytology were managed as per
routine recommendations; those with normal cytology and positive high-risk HPV test results were invited for
repeated testing in 18 months.
Results: Cross-reactivity to low-risk genotypes was detected in 109 (2.2 %) out of 5022 samples on HC2, 62 (1.2 %)
on cobas, and 35 (0.7 %) on APTIMA with only 10 of the samples cross-reacting on all 3 assays. None of the 35
genotypes was detected in 49 (1.0 %), 162 (3.2 %), and 56 (1.1 %) samples, respectively. In primary screening at age
30 to 65 years (n = 2859), samples of 72 (25 %) out of 289 with high-risk infections on HC2 and < CIN2 histology
were due to cross-reactivity. On cobas, this was 106 (26 %) out of 415, and on APTIMA 48 (21 %) out of 224.
Conclusions: Despite manufacturer claims, all three assays showed cross-reactivity. In primary cervical screening at
age ≥30 years, cross-reactivity accounted for about one quarter of false positive test results regardless of the assay.
Cross-reactivity should be addressed in EU tenders, as this primarily technical shortcoming imposes additional costs
on the screening programmes.
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Background
High-risk human papillomavirus (HPV) is a necessary
cause of cervical cancer. HPV testing is currently widely
used for triage of women with cytological abnormalities
i.e. atypical squamous cells of undetermined significance
(ASCUS) and as a test of cure [1, 2]. In European coun-
tries including Norway, the Netherlands, Italy, Spain,
Denmark, and Sweden primary HPV-based cervical
screening is being piloted or a full-scale roll out is
planned. In the USA, primary screening is at present
undertaken as co-testing using cytology and HPV test-
ing, but new recommendations advocate stand-alone
HPV testing [3]. The role of HPV testing in screening is
supported by the objectivity of test result read-outs and
an improved protection of women from developing cer-
vical cancer compared to cytology [4]. However, it is less
specific for disease because most HPV infections clear
spontaneously without leading to abnormalities. This
means that false-positive test results, and the associated
unnecessary diagnostic procedures, are common.
More than 100 HPV genotypes have been identified, of
which 13 are high-risk (16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, and 68) [5]. Cross-reactivity of HPV assays to
untargeted, low-risk (non-oncogenic), genotypes has
been considered as a possible cause of false-positive
HPV test results.
Cross-reactivity has only been systematically and inde-
pendently evaluated for the most widely used assay, hy-
brid capture II (HC2), where it was most frequently due
to low-risk genotypes 53, 66, and 70 [6–11]. The inten-
sity of the positive signal in cross-reacting samples
tended to be relatively weak [7, 8, 10], and the likelihood
of cross-reactivity increased in multiple low-risk infec-
tions [6]. Most importantly, cross-reacting samples were
rarely associated with high-grade cervical intraepithelial
neoplasia (CIN) [6–8, 10]—clearly showing that cross-
reactivity contributes to false-positive test results.
For more recently introduced commercially available
assays, cross-reactivity profiles have not been independ-
ently established. Based on the data from the Danish
Horizon study, we evaluated the frequency of cross-
reactivity for HC2, cobas, and APTIMA in a large split-
sample study.
Methods
Setting
In Denmark, women aged 23–65 years are invited for
cytology-based cervical screening every three (age
<50 years) or every 5 years (≥50 years). The design of
the Horizon study was described in detail previously
[12–17]. In short, consecutive SurePath samples from
5034 women evaluated at the Department of Pathology,
Copenhagen University Hospital, Hvidovre, were tested
with HC2, cobas, and APTIMA, and genotyped by
CLART HPV2 Assay (Genomica, Madrid, Spain). All
SurePath cytology was read under routine conditions
following the Bethesda 2011 system using FocalPoint
Slide Profiler and Imaging systems. Women with abnor-
mal cytology (≥ASCUS) were managed according to rou-
tine screening recommendations. Women with normal
cytology and a positive test result on at least one of the
four HPV assays were additionally invited in 1.5 year for
repeated cytology and HPV testing. For each woman,
the worst histological diagnosis until December 2013, i.e.
in approximately 2.5 years after the baseline testing, was
retrieved from the nationwide Danish Pathology Data
Bank (Patobank) [18].
HPV testing
Cytology post-quot material was used for HC2 testing.
The remaining HPV testing was undertaken on the
original residual material diluted with SurePath (ap-
proximately 1:1). All testing was undertaken in strict
concordance with the protocols issued and agreed upon
with the manufacturers. The instrumentation was sup-
plied and maintained by the manufacturers. Cut-offs for
positive test results were set by the manufacturers: RLU/
CO ≥1.0 for HC2; CT ≤40.5, ≤40.0, and ≤40.0 for cobas’s
channels 16, 18, and other high-risk, respectively; and S/
CO ≥0.5 for APTIMA.
CLART was used as the full genotyping reference
assay. This L1 DNA PCR assay reports 35 genotypes in-
dividually, including the 13 high-risk and 22 low-risk (6,
11, 26, 40, 42, 43, 44, 53, 54, 61, 62, 66, 70, 71, 72, 73,
81, 82, 83, 84, 85, and 89). It uses modified PGMY09/11
primers with amplification products hybridized onto a
low density microarray. The amplified viral sequences
are approximately 465 base pairs (bp) long, dependent
on the genotype. Visualization was performed and there-
after automatically read on the CLART array reader
(Genomica). A spiked rhCFTR plasmid is used as
process control, while a DNA control of the human
CFTR gene validates material sufficiency.
HC2 detects, collectively, the 13 high-risk HPV geno-
types. The assay is based on hybridisation of viral DNA
to a high-risk RNA probe cocktail. No retest range was
used. Cobas is a real-time PCR analysis detecting the 13
high-risk genotypes plus genotype 66. The assay separ-
ately identifies genotypes 16 and 18, while the remaining
12 are detected collectively (“other high-risk”). The
amplicons are approximately 165 bp long. APTIMA detects
E6/E7 mRNA expression of the 13 high-risk genotypes plus
genotype 66 collectively using transcription-mediated amp-
lification (TMA).
Statistical analysis
Cross-reacting samples were defined as those with posi-
tive test results without evidence of high-risk HPV
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genotypes by CLART. A sample cross-reacting to low-
risk genotypes was defined as one with a positive test
result in which CLART detected only genotypes not tar-
geted by the evaluated assay. This means that for HC2,
cross-reactivity to low-risk genotypes was measured for
22 genotypes including genotype 66. For cobas and
APTIMA assays, evaluation was undertaken for 21 geno-
types, as they are both designed to detect genotype 66.
Samples with a positive test result cross-reacting to un-
confirmed genotypes, defined as non-CLART geno-
types, were included in the analysis but evaluated
separately [7, 8, 11]. From 5034 samples, 12 were in-
valid on CLART, reducing the number of eligible
samples to 5022.
Assay-specific absolute cross-reactivity was defined as
the proportion of cross-reacting samples among all stud-
ied samples, and assay-specific relative cross-reactivity
as the proportion of cross-reacting samples among all
samples with a positive test result. Genotypes most fre-
quently involved in cross-reactivity were determined
based on the distributions in single infections.
We used signal strength as a relative indicator of the
amount of the viral target input material, and described
its distribution with the median and interquartile range.
If cobas returned a positive test result on more than one
channel, the channel with the strongest signal was in-
cluded in the analysis.
False-positive samples were defined as samples with a
positive test result that were not followed by a diagnosis
of ≥CIN2. The origin of the samples was defined as
primary screening or referral population using informa-
tion on the women’s testing histories registered in the
Patobank since January 2000. Referral population sam-
ples (n = 887) were defined as either primary screening
samples showing abnormal cytology at any age, or as
samples with a recent abnormality, regardless of age and
cytology. A recent abnormality was defined as a preceding
cervical cancer diagnosis, a histological CIN diagnosis in
≤3 years, cytological low-grade squamous intraepithelial
lesions (LSIL) or worse, inadequate cytology, or a positive
HPV test result in ≤12 months, and less abnormal cervical
cytological or histological diagnoses in ≤15 months. Sam-
ples without a recent abnormality were predominantly
screening samples. Since HPV screening has been discour-
aged for younger women [19], the primary screening
population was restricted to 30–65 years (n = 2859).
Cross-reactivity was compared between different groups
by calculating relative proportions and their 95 % confi-
dence intervals by assuming lognormal distribution.
Results
Cross-reactivity by assay
Among 5022 unselected samples (range: 16–89 years,
mean = 37.3, SD = 12.3, 4748 (95 %) 23–65 years), 1262
(25 %) had at least one of the 13 high-risk genotypes de-
tected by CLART, and 1333 (27 %) when genotype 66
was included. Furthermore, 1024 (20 %) were positive
on HC2, 1345 (27 %) on cobas, and 838 (17 %) on
APTIMA (Table 1). Of these, CLART detected only low-
risk genotypes in 109 samples for HC2, 62 for cobas,
and 35 for APTIMA. Acknowledging that cross-
reactivity was assessed based on one more genotype for
HC2 than for cobas and APTIMA (genotype 66), abso-
lute cross-reactivity to low-risk genotypes was 2.2, 1.2,
and 0.7 %, respectively, and relative cross-reactivity was
10.6, 4.6, and 4.2 %, respectively. Absolute cross-
reactivity to low-risk genotypes was significantly higher
for HC2 than for the other assays, and that of cobas was
significantly higher compared to APTIMA. Relative
cross-reactivity to low-risk genotypes was significantly
higher for HC2, and statistically similar between cobas
and APTIMA.
Absolute cross-reactivity to unconfirmed genotypes
was 1.0 % on HC2, 3.2 % on cobas, and 1.1 % on
APTIMA, and relative cross-reactivity was 4.8, 12.0, and
6.7 %, respectively. Absolute cross-reactivity to uncon-
firmed genotypes was significantly higher for cobas than
for the other two assays.
Cross-reactivity to low-risk genotypes was more fre-
quent in younger women and in abnormal cytology
(Table 2). Cross-reactivity to unconfirmed genotypes did
not show a trend by age, but was, for cobas and
APTIMA, somewhat more frequent in normal cytology.
Relative cross-reactivity to low-risk genotypes on all
three assays was not significantly different in the referral
compared to the primary screening population. Absolute
cross-reactivity to low-risk genotypes, however, was sig-
nificantly lower on HC2 and cobas in the screening than
in the referral population. This is probably a reflection
of a lower HPV prevalence in primary screening. The
patterns were different for cross-reactivity to uncon-
firmed genotypes, with relative cross-reactivity being
more frequent in the screening than in the referral
population (Table 1).
Cross-reactivity concordance?
Only 10 (6 %) of 157 samples cross-reacting to low-risk
genotypes did so on all three assays (Fig. 1a). Of the 109
HC2 cross-reacting samples, 73 (67 %) were negative on
cobas and APTIMA, and 24 of these involved genotype
66. Cobas had 36 (58 %) unique cross-reacting samples
out of all 62, whereas APTIMA had 9 (26 %) out of 35.
In total, 75 % of the 157 samples cross-reacting to low-
risk genotypes were positive on only one assay. Among
the 223 samples cross-reacting to unconfirmed geno-
types, concordance was similarly low, with 12 (5 %) be-
ing positive on all three assays; 86 % of 223 samples
were positive on only one (Fig. 1b).
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Table 1 Samples cross-reacting to low-risk and unconfirmed genotypes
Total (any of the
three assays)
HC2 cobas APTIMA
Overall
Positive test results, Total population
(N = 5022)
1505 1024 (20.4 %) 1345 (26.8 %)a 838 (16.7 %)a
Positive test results, Primary screening
population age 30–65 years (N = 2859)
553 335 (11.7 %) 464 (16.2 %) 270 (9.4 %)
Positive test results, Referral population
(N = 887)
499 401 (45.2 %) 453 (51.1 %) 332 (37.4 %)
Cross-reactivity to
low-risk genotypes
Total population (N = 5022)
Cross-reacting samples 157 109 62 35
Absolute cross-reactivity – 109/5022 (2.2 %) 62/5022 (1.2 %) 35/5022 (0.7 %)
Absolute cross-reactivity (vs. HC2) – 1 (reference) 0.6 (0.4 to 0.8) 0.3 (0.2 to 0.5)
Relative cross-reactivity – 109/1024 (10.6 %) 62/1345 (4.6 %) 35/838 (4.2 %)
Relative cross-reactivity (vs. HC2) – 1 (reference) 0.4 (0.3 to 0.6) 0.4 (0.3 to 0.6)
Primary screening population, age
30–65 years (N = 2859)
Cross-reacting samples 61 43 20 13
Absolute cross-reactivity – 43/2859 (1.5 %) 20/2859 (0.7 %) 13/2859 (0.5 %)
Absolute cross-reactivity (vs. HC2) – 1 (reference) 0.5 (0.3 to 0.8) 0.3 (0.2 to 0.6)
Relative cross-reactivity – 43/335 (12.8 %) 20/464 (4.3 %) 13/270 (4.8 %)
Relative cross-reactivity (vs. HC2) – 1 (reference) 0.3 (0.2 to 0.6) 0.4 (0.2 to 0.7)
Referral population (N = 887)
Cross-reacting samples 58 47 16 8
Absolute cross-reactivity – 47/887 (5.3 %) 16/887 (1.8 %) 8/887 (0.9 %)
Absolute cross-reactivity (vs. HC2) – 1 (reference) 0.3 (0.2 to 0.6) 0.2 (0.1 to 0.4)
Relative cross-reactivity – 47/401 (11.7 %) 16/453 (3.5 %) 8/332 (2.4 %)
Relative cross-reactivity (vs. HC2) – 1 (reference) 0.3 (0.2 to 0.5) 0.21 (0.1 to 0.4)
Primary screening vs. referral population
Absolute cross-reactivity (95 %
confidence interval)
– 0.3 (0.2 to 0.4) 0.4 (0.2 to 0.7) 0.5 (0.2 to 1.2)
Relative cross-reactivity (95 %
confidence interval)
– 1.1 (0.7 to 1.6) 1.2 (0.6 to 2.3) 2.0 (0.8 to 4.8)
Cross-reactivity to
unconfirmed genotypes
Total population (N = 5022)
Cross-reacting samples 223 49 162 56
Absolute cross-reactivity – 49/5022 (1.0 %) 162/5022 (3.2 %) 56/5022 (1.1 %)
Absolute cross-reactivity (vs. HC2) – 1 (reference) 3.3 (2.4 to 4.5) 1.1 (0.8 to 1.7)
Relative cross-reactivity – 49/1024 (4.8 %) 162/1345 (12.0 %) 56/838 (6.7 %)
Relative cross-reactivity (vs. HC2) – 1 (reference) 2.5 (1.8 to 3.4) 1.4 (1.0 to 2.0)
Primary screening population, age
30–65 years (N = 2859)
Total positive test results 553 335 (11.7 %) 464 (16.2 %) 270 (9.4 %)
Cross-reacting samples 126 30 87 36
Absolute cross-reactivity – 30/2859 (1.0 %) 87/2859 (3.0 %) 36/2859 (1.3 %)
Absolute cross-reactivity (vs. HC2) – 1 (reference) 2.9 (1.9 to 4.4) 1.2 (0.7 to 1.9)
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One of the six samples cross-reacting to low-risk ge-
notypes with histologically confirmed high-grade lesions
was a cervical cancer, detected by all three assays
(Table 3). Of the five CIN2/3, one was detected by HC2
and APTIMA (CIN 2), two by HC2 and cobas (one
CIN2 and one CIN3), and two (both CIN3) only by
HC2. One CIN3 was detected by all three assays but
CLART detected no genotypes.
Multiple infections
As also described previously [7], the likelihood of an
assay returning a positive test result increased with the
number of genotypes present in the sample (Table 4).
This was observed for all three assays.
Signal strength
For all three assays, the median signal strength was
weaker for samples cross-reacting to low-risk genotypes
than for samples with high-risk genotypes confirmed by
CLART (Fig. 2). In samples cross-reacting to uncon-
firmed genotypes, the median signal strength levels
tended to be lower than in samples cross-reacting to
low-risk genotypes.
Most frequently cross-reacting low-risk genotypes
For HC2, the most frequent cross-reacting infections
were 66 (20), 70 (19), 53 (18), and 82 (14 %; Table 5).
Several other genotypes also showed cross-reactivity, but
in <10 % of all infections. On cobas, the frequent cross-
reacting genotypes were 70 (19) and 61 (15 %). On
APTIMA, although based on very low numbers, geno-
types 70 (36), 62 (16), 61 (12), 82 (12), and 83 (12 %)
dominated. Genotype distributions were similar in mul-
tiple infections, with genotypes 44, 71, and 72 detected
only in cross-reacting samples with multiple infections.
Genotypes 40, 43, 85, and 89, all very infrequent in this
population [12], did not appear to be involved in cross-
reactivity.
On cobas, 5 % of samples with a positive test result on
channel 16 alone contained only low-risk genotypes
(Table 6). For channels 18 and other high-risk, the pro-
portions were similar at 7 and 6 %, respectively. Of all
samples cross-reacting to low-risk genotypes, 77 % (48/
62) were on other high-risk channel alone. Similar pro-
portions, in the range of 14-18 % for the three channels,
were also found for cross-reactivity to unconfirmed
genotypes.
Effect of cross-reactivity on the proportions of women
with false-positive test results
Cross-reactivity explained a measurable part of all false-
positive test results (Table 7). In primary screening at
30–65 years, about one in four false-positive HPV test
result was due to cross-reactivity. Had there been no
cross-reactivity, 7.6 instead of 10.1 % of women would
have had a false-positive test result on HC2. On cobas,
this would have been 10.8 % instead of 14.5 %, and 6.2 %
instead of 7.8 % on APTIMA.
Discussion
General findings
In Danish routine SurePath samples, the patterns of
HPV cross-reactivity for HC2 resembled those that
were described previously. Cobas has been advertised
as a HPV assay that does not cross-react to low-risk ge-
notypes [20], whereas APTIMA’s package insert cites
cross-reactivity to genotypes 26, 67, 70, and 82, which
are phylogenetically related to high-risk genotypes [21].
Table 1 Samples cross-reacting to low-risk and unconfirmed genotypes (Continued)
Relative cross-reactivity – 30/335 (9.0 %) 87/464 (18.8 %) 36/270 (13.3 %)
Relative cross-reactivity (vs. HC2) – 1 (reference) 2.1 (1.4 to 3.1) 1.5 (0.9 to 2.4)
Referral population (N = 887)
Total positive test results 499 401 (45.2 %) 453 (51.1 %) 332 (37.4 %)
Cross-reacting samples 37 9 27 8
Absolute cross-reactivity – 9/887 (1.0 %) 27/887 (3.0 %) 8/887 (0.9 %)
Absolute cross-reactivity (vs. HC2) – 1 (reference) 3.0 (1.4 to 6.3) 0.9 (0.3 to 2.3)
Relative cross-reactivity – 9/401 (2.2 %) 27/453 (6.0 %) 8/332 (2.4 %)
Relative cross–reactivity (vs. HC2) – 1 (reference) 2.3 (1.3 to 5.6) 1.1 (0.4 to 2.8)
Primary screening vs. referral population
Absolute cross-reactivity (95 %
confidence interval)
– 1.0 (0.5 to 2.2) 1.0 (0.7 to 1.5) 1.4 (0.7 to 3.0)
Relative cross-reactivity (95 %
confidence interval)
– 4.0 (1.9 to 8.3) 3.1 (2.1 to 4.7) 5.5 (2.6 to 11.7)
aGenotype 66 was the only detected genotype among those that are targeted by cobas or APTIMA in 31 (2.3 %) and 11 (1.3 %), respectively, of the samples with
positive test results
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In our study, however, both appeared to cross-react to
low-risk genotypes from various phylogenetic clades in-
cluding those that do not include high-risk genotypes.
The frequency of cross-reactivity to low-risk genotypes
was most frequently observed on HC2. The number of
samples in which none of the 35 CLART genotypes was
detected was surprisingly high especially for cobas.
When both types of cross-reactivity were combined,
about a quarter of samples with a false-positive test
result in primary screening at age 30–65 years appeared
to be cross-reacting on any of the three assays.
For all three assays, the most frequently involved
cross-reacting genotypes were 53, 61, 62, 70, 82, and for
HC2 also genotype 66. Cross-reacting samples exhibited
relatively weak signal strengths, and few were associated
with ≥CIN2. Cross-reactivity to low-risk genotypes was
more frequent in young women, in abnormal cytology,
and after previous abnormalities. Cross-reactivity to
unconfirmed genotypes, on the other hand, tended to be
more frequent in normal cytology. There were only a
few samples that cross-reacted on all three assays,
suggesting that cross-reactivity is driven by technology.
Table 2 Characteristics of cross-reacting samples in 5022 women
Total (any of the three assays) HC2 cobas APTIMA
Cross-reactivity to low-risk genotypes
Age
<30 years (n = 1683) 75 51 (3.0 %) 34 (2.0 %) 15 (0.9 %)
≥30 years (n = 3339) 82 58 (1.7 %) 28 (0.8 %) 20 (0.6 %)
Concurrent cytology
Normal (n = 4630) 116 71 (1.5 %) 56 (1.2 %) 29 (0.6 %)
Abnormal (n = 367) 40 37 (10.1 %) 6 (1.6 %) 6 (1.6 %)
Inadequate (n = 25) 1 1 (4.0 %) 0 (0.0 %) 0 (0.0 %)
Histology outcome
CIN2 (n = 60) 2 2 (3.3 %) 0 (0.0 %) 1 (1.7 %)
CIN3 or worse (n = 118)a 4 4 (3.4 %) 2 (1.7 %) 1 (0.8 %)
Cross-reactivity to unconfirmed genotypes
Age
<30 years (n = 1683) 73 15 (0.9 %) 56 (3.3 %) 15 (0.9 %)
≥30 years (n = 3339) 150 34 (1.0 %) 106 (3.2 %) 41 (1.2 %)
Concurrent cytology
Normal (n = 4630) 214 44 (1.0 %) 157 (3.4 %) 54 (1.2 %)
Abnormal (n = 367) 7 4 (1.1 %) 3 (0.8 %) 2 (0.5 %)
Inadequate (n = 25) 2 1 (4.0 %) 2 (8.0 %) 0 (0.0 %)
Histology outcome
CIN2 (n = 60) 0 0 (0.0 %) 0 (0.0 %) 0 (0.0 %)
CIN3 or worse (n = 118)a 1 1 (0.8 %) 1 (0.8 %) 1 (0.8 %)
aOf which three cases of cervical cancer
Fig. 1 Inter-assay distribution of samples cross-reacting to low-risk genotypes a and unconfirmed genotypes b
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Strengths and weaknesses
This is the first study that systematically evaluated
cross-reactivity on three widely used assays in a split-
sample study. It is, furthermore, the first independent
study on cobas and APTIMA. We used consecutive,
unselected, samples from women undergoing routine
screening or follow-up of abnormalities. All testing was
undertaken in the same laboratory by the same staff.
This split-sample design helped eliminate variability in
study populations and laboratory performance. Samples
Table 3 Women with CIN2 or higher: Screening test results for cross-reacting samples
HPV test result
Case number Grade of CIN Cytology Detected genotypes
by CLART
HC2, relative light
units per cut-off
cobas, cycle threshold APTIMA, signal per
cut-off
Cross-reactivity to low-risk genotypes
1 Grade 2 Atypical 70, 71, 81, 84 Positive
(cross-reacting), 9.55
Negative Positive
(cross-reacting), 3.44
2 Grade 2 Normal 53, 66, 83 Positive
(cross-reacting), 3.58
Positive, other high-risk
genotypes: 30.1
Negative
3 Grade 3 Low-grade 82 Positive
(cross-reacting), 2.70
Positive (cross-reacting),
genotype 16: 37.3
Negative
4 Grade 3 High-grade 42, 61 Positive
(cross-reacting), 5.74
Negative Negative
5 Grade 3 High-grade 82 Positive
(cross-reacting), 11.06
Negative Negative
6 Cervical cancer High-grade 70 Positive
(“cross-reacting”), 21.43
Positive (“cross-reacting”),
genotype 18: 39.5
Positive
(“cross-reacting”), 0.84
Cross-reactivity to unconfirmed genotypes
7 Grade 3 Atypical None Positive
(CLART negative), 2.14
Positive (CLART negative),
other high-risk genotypes: 34.0
Positive
(CLART negative), 14.92
Table 4 Breakdown of positive and negative test results on HC2, cobas, and APTIMA, by the number and risk level of HPV
genotypes detected on CLART
Risk level of detected
genotypes
Number of
genotypes
HC2 cobas APTIMA
Negative test
result
Positive test
result
Total Negative test
result
Positive test
result
Total Negative test
result
Positive test
result
Total
Only low-risk 1 410 (84 %) 79 (16 %) 489 390 (89 %) 47 (11 %) 437 412 (94 %) 25 (6 %) 437
2 72 (80 %) 18 (20 %) 90 66 (85 %) 12 (15 %) 78 73 (94 %) 5 (6 %) 78
3 18 (69 %) 8 (31 %) 26 16 (84 %) 3 (16 %) 19 16 (84 %) 3 (16 %) 19
≥4 6 (60 %) 4 (40 %) 10 10 (100 %) 0 (0 %) 10 8 (80 %) 2 (20 %) 10
Total 506 (82 %) 109 (18 %) 615 482 (89 %) 62 (11 %) 544 509 (94 %) 35 (6 %) 544
Only high-risk 1 245 (50 %) 242 (50 %) 487 143 (27 %) 396 (73 %) 539 319 (59 %) 220 (41 %) 539
2 19 (10 %) 169 (90 %) 188 8 (5 %) 146 (95 %) 153 45 (29 %) 109 (71 %) 153
3 3 (6 %) 45 (94 %) 48 1 (2 %) 53 (98 %) 54 13 (24 %) 41 (76 %) 54
≥4 0 (0 %) 12 (100 %) 12 0 (0 %) 18 (100 %) 17 1 (6 %) 17 (94 %) 17
Total 267 (36 %) 468 (64 %) 735 152 (20 %) 613 (80 %) 765 378 (49 %) 387 (51 %) 765
Low-risk and high-risk 2 72 (46 %) 86 (54 %) 158 42 (20 %) 162 (79 %) 205 106 (52 %) 98 (48 %) 205
3 38 (25 %) 116 (75 %) 154 16 (10 %) 139 (90 %) 155 56 (36 %) 99 (64 %) 155
≥4 19 (9 %) 196 (91 %) 215 2 (1 %) 207 (99 %) 210 46 (22 %) 163 (78 %) 210
Total 129 (24 %) 398 (76 %) 527 60 (11 %) 508 (89 %) 568 208 (37 %) 360 (63 %) 568
No genotypes 0 3096 (98 %) 49 (2 %) 3145 2981 (95 %) 162 (5 %) 3143a 3089 (98 %) 56 (2 %) 3145
Total – – – 5022 – – 5020a – – 5022
aTwo samples had an invalid test result on cobas. For both samples, HC2 and APTIMA test results were negative; CLART detected no genotypes; cytology on one
sample was normal, and inadequate on the other sample
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were stored in SurePath, a liquid-based cytology medium
that is frequently used in Europe and the USA. Samples
were heated to reverse the covalent bindings between
genomic material and protein complexes induced by
SurePath’s formaldehyde. This procedure renders the
genetic material accessible for analysis [22]. We could
determine the reason for sampling, enabling us to com-
pare the frequency of cross-reactivity in the primary
screening and referral populations. In line with our pre-
vious analyses [17], we again conclude that the data from
referral populations cannot be generalised to the primary
screening context.
Biological material can deteriorate or disintegrate upon
storage. Prolonged storage could impact the data espe-
cially in samples with weak signal strength, a characteristic
we observed in cross-reacting samples. Thus, using fresh
samples, as we did in our study [12, 14, 16], may be the
only reliable way to evaluate and compare the frequency
of cross-reactivity. Moreover, in concordance with the
protocol and by approval from the manufacturers, we di-
luted the original samples approximately 1:1. This can be
seen as a weakness. However, all three assays rely on test-
ing aliquots of 0.5–1 ml out of the typically 10 (SurePath)
or 20 ml (ThinPrep) available from liquid-based cytology
media. Hence, assay designs should be robust enough to
handle sampling variability in terms of cellularity.
There is no internationally agreed standard genotyping
assay, so the choice of a reference assay can be discussed
[7, 11]. No HPV assay, with or without genotyping,
seems to detect all targeted infections [17, 23]. CLART
is a CE-IVD marked assay, not “research use only”, and
is currently used in a number of regional European
screening programmes. It has been evaluated in clinical
settings [12, 24–28], and its analytical performance has
been compared to, for example, linear array (LA) as part
of the latest WHO HPV LabNet Proficiency Studies [29].
There, both assays showed a high analytical sensitivity for
genotypes 16 and 18, even at low plasmid concentrations.
CLART more often correctly detected genotypes 6, 11, 31,
33, 35, 51, 52, 58, 59, and 66 compared to LA, but the latter
was better at detecting genotypes 45 and 56 at high plasmid
concentrations. Finally, we chose CLART as a reference
assay given that it reports the detected genotypes using a
computer algorithm rather than manual reading. This en-
ables a more reproducible and objective assay read-out.
In this study, CLART detected high-risk genotypes
or genotype 66 in 27 % of all samples. This was com-
parable to the proportion in which cobas detected
high-risk genotypes (27 %), and higher than the pro-
portions detected by HC2 (20 %) and APTIMA
(17 %). In a different study from our laboratory using
data from 401 women with abnormal cytology [28],
we also compared the detection of low-risk genotypes
between CLART and LA. The detection of several
genotypes found to be most frequently cross-reacting
in the present study (53, 61, 66, and 70) was very
similar, with an overall agreement of 98–99 %. For
Fig. 2 Signal strength of samples with a positive test result on
HC2, cobas, or APTIMA. Test results are stratified by whether
CLART detected at least one of the high-risk genotypes, only
low-risk genotypes, or no genotypes. Medians with interquartile
ranges (IQR). HC2: High-risk genotypes (n = 866), median = 28.1,
IQR: 5.6 to 157.4. Low-risk genotypes (n = 109), median = 5.2,
IQR: 2.2 to 24.1. No genotypes (n = 49), median = 3.0, IQR: 1.7 to
8.8. cobas: High-risk genotypes (n = 1121), median = 31.1, IQR:
27.1 to 35.0. Low-risk genotypes (n = 62), median = 37.8, IQR: 34.2
to 38.9. No genotypes (n = 162), median = 38.9, IQR: 36.2 to 39.5.
APTIMA: High-risk genotypes (n = 747), median = 10.8, IQR: 8.0 to
12.4. Low-risk genotypes (n = 35), median = 5.4, IQR: 1.5 to 8.9.
No genotypes (n = 56), median = 3.2, IQR: 1.3 to 7.3
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the other two most frequently cross-reacting geno-
types (62 and 82), the level of agreement was slightly
lower (96 and 93 %, respectively).
However, a general limitation of CLART is the relatively
long amplicons generated from the modified PGMY09/11
primers, meaning that partially complete amplicons or un-
specific amplifications are less likely to be reported as
positive test findings compared to genotyping assays rely-
ing on shorter amplicons, such as LA. Furthermore, in
our study CLART detected only a genotype 70 infection
in one case of cervical cancer associated where cobas de-
tected genotype 18 [15]. A CIN3 case was positive on all
three evaluated assays but negative on CLART. The
remaining five cases of CIN2/3 that were apparently
missed by CLART were positive only on one or two of the
evaluated assays. Given that the histology was read under
routine circumstances, false-positive histology findings
cannot be entirely ruled out [8].
Finally, the cross-reactivity estimates for APTIMA
should be interpreted with respect to the fact that it de-
tects HPV mRNA, whereas CLART detects HPV DNA.
Therefore, APTIMA should ideally have been evaluated
against an mRNA genotyping assay. However, no such
assay exists.
Comparison with the literature
Castle et al. [6] studied cross-reactivity patterns of HC2
probe B against the combined test results of MY09/11
Amplitaq DNA polymerase and Amplitaq Gold DNA
polymerase in an unscreened population (n = 954). Of all
single low-risk genotype infections, HC2 cross-reacted
in 20 %, most frequently because of genotypes 11, 53,
61, 66, 67, 70, 71, and 81. Six (6 %) of 108 ≥CIN3 were
detected in cross-reacting samples, and 5 (5 %) in sam-
ples with no detected genotypes. In normal cytology,
cross-reacting samples increased the sensitivity for high-
grade CIN, whereas in abnormal cytology, they primarily
decreased the specificity. Very similar results were found
in the ALTS trial, using archived samples (collected in
STM media or PreservCyt) from 3179 women with
ASCUS/LSIL [7]. Cross-reactivity, assessed against the
combined test results of line blot (a prototype for LA)
and LA assays, was observed in 8 % of samples with a
positive HC2 test result (4 % of all samples), whereas
2 % (1 %) had no detected genotypes on the reference
assays. The most frequently involved genotypes were 66,
70, and 82, and the likelihood of cross-reactivity in-
creased in multiple low-risk infections. Cross-reacting
samples had weaker signals than samples with high-risk
Table 5 Genotype distribution in samples cross-reacting to low-risk genotypes
Genotype Phylogenetic
clade
High-risk genotypes
in the same
phylogenetic clade
HC2 cobas APTIMA
Single
infections (%)
Multiple
infections (%)
Single
infections (%)
Multiple
infections (%)
Single
infections (%)
Multiple
infections (%)
6 α10 None 2 (2.5 %) 5 (6.6 %) 3 (6.4 %) 4 (12.1 %) 0 (0.0 %) 2 (7.4 %)
11 α10 None 0 (0.0 %) 0 (0.0 %) 1 (2.1 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %)
26 α5 51 0 (0.0 %) 0 (0.0 %) 1 (2.1 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %)
42 α1 None 5 (6.3 %) 3 (3.9 %) 4 (8.5 %) 0 (0.0 %) 2 (8.0 %) 2 (7.4 %)
44 α10 None 0 (0.0 %) 3 (3.9 %) 0 (0.0 %) 2 (6.1 %) 0 (0.0 %) 0 (0.0 %)
53 α6 56 14 (17.7 %) 10 (13.2 %) 4 (8.5 %) 4 (12.1 %) 0 (0.0 %) 2 (7.4 %)
54 α13 None 2 (2.5 %) 2 (2.6 %) 2 (4.3 %) 2 (6.1 %) 0 (0.0 %) 1 (3.7 %)
61 α3 None 2 (2.5 %) 7 (9.2 %) 7 (14.9 %) 4 (12.1 %) 3 (12.0 %) 1 (3.7 %)
62 α3 None 2 (2.5 %) 5 (6.6 %) 4 (8.5 %) 2 (6.1 %) 4 (16.0 %) 3 (11.1 %)
66 α6 56 16 (20.3 %) 8 (10.5 %) Not relevant Not relevant Not relevant Not relevant
70 α7 18, 39, 45, 59, 68 15 (19.0 %) 8 (10.5 %) 9 (19.1 %) 3 (9.1 %) 9 (36.0 %) 4 (14.8 %)
71 α15 None 0 (0.0 %) 1 (1.3 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) 1 (3.7 %)
72 α3 None 0 (0.0 %) 1 (1.3 %) 0 (0.0 %) 1 (3.0 %) 0 (0.0 %) 1 (3.7 %)
73 α11 None 1 (1.3 %) 2 (2.6 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) 1 (3.7 %)
81 α3 None 3 (3.8 %) 4 (5.3 %) 3 (6.4 %) 2 (6.1 %) 1 (4.0 %) 2 (7.4 %)
82 α5 51 11 (13.9 %) 5 (6.6 %) 3 (6.4 %) 2 (6.1 %) 3 (12.0 %) 2 (7.4 %)
83 α3 None 2 (2.5 %) 7 (9.2 %) 3 (6.4 %) 3 (9.1 %) 3 (12.0 %) 2 (7.4 %)
84 α3 None 4 (5.1 %) 5 (6.6 %) 3 (6.4 %) 4 (12.1 %) 0 (0.0 %) 3 (11.1 %)
# Genotypes – – 79 (100 %) 76 (100 %) 47 (100 %) 33 (100 %) 25 (100 %) 27 (100 %)
# Samples – – 79 30 47 15 25 10
No woman had a cross-reacting sample on any of the three HPV assays because of genotypes 40 (α8), 43 (α8), 85 (α7), or 89 (α3)
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Table 6 Genotype distribution in cross-reacting samples on cobas
Genotype cobas test result
Genotype 16 Genotype 18 Other high-risk
genotypes
16 and 18 16 and other
high-risk
18 and other
high-risk
16, 18, and
other high-risk
Total
6 1 0 6 0 0 0 0 7
11 0 0 1 0 0 0 0 1
26 0 0 1 0 0 0 0 1
42 2 0 2 0 0 0 0 4
44 0 0 2 0 0 0 0 2
53 0 1 7 0 0 0 0 8
54 1 1 2 0 0 0 0 4
61 3 1 7 0 0 0 0 11
62 0 0 6 0 0 0 0 6
70 0 2 10 0 0 0 0 12
72 0 0 1 0 0 0 0 1
81 1 0 3 0 0 1 0 5
82 1 0 4 0 0 0 0 4
83 0 0 6 0 0 0 0 6
84 0 0 6 0 1 0 0 7
# Samples with a positive test
result
168 (100 %) 56 (100 %) 858 (100 %) 6 (100 %) 167 (100 %) 71 (100 %) 19 (100 %) 1345 (100 %)
# Samples with only low-risk
genotypes
8 (4.8 %) 4 (7.1 %) 48 (5.6 %) 0 (0.0 %) 1 (0.6 %) 1 (1.4 %) 0 (0.0 %) 62 (4.6 %)
# Samples with no detected
genotype
26 (15.5 %) 10 (17.9 %) 116 (13.5 %) 0 (0.0 %) 8 (4.8 %) 2 (2.8 %) 0 (0.0 %) 162 (12.0 %)
No woman had a cross-reacting sample on cobas because of genotypes 40, 43, 71, 73, 85, or 89
Table 7 Effect of cross-reactivity on the proportion of women with positive and false-positive HPV test results
HC2 cobas APTIMA
N (%) ≥CIN2 N (%) ≥CIN2 N (%) ≥CIN2
Primary screening, 30–65 years (n = 2859)
All positive test results 335 (11.7 %) 46 464 (16.2 %) 49 270 (9.4 %) 46
Samples with high-risk genotypes 262 (9.2 %) 45 357 (12.5 %) 48 221 (7.7 %) 45
Cross-reacting samples 73 (2.6 %) 1 107 (3.7 %) 1 49 (1.7 %) 1
False-positive test results, all (%) 289 (10.1 %) – 415 (14.5 %) – 224 (7.8 %) –
False-positive test results, after exclusion of cross-reactivity (%) 217 (7.6 %) – 309 (10.8 %) – 176 (6.2 %) –
Proportion of false-positive test results due to cross-reactivity 25 % – 26 % – 21 % –
Referral population (n = 887)
All positive test results 401 (45.2 %) 124 453 (51.1 %) 123 332 (37.4 %) 112
Samples with high-risk genotypes 345 (38.9 %) 117 410 (46.2 %) 120 316 (35.6 %) 109
Cross-reacting samples 56 (6.3 %) 7 43 (4.8 %) 3 16 (1.8 %) 3
False-positive test results, all (%) 277 (31.2 %) – 330 (37.2 %) – 220 (24.8 %) –
False-positive test results, after exclusion of cross-reactivity (%) 228 (25.7 %) – 290 (32.7 %) – 207 (23.3 %) –
Proportion of false-positive test results due to cross-reactivity 18 % – 12 % – 6 % –
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genotypes. Out of 272 ≥CIN3, three (1 %) were from
women with cross-reacting samples, and one (<1 %)
from a woman with no detected genotypes. In a Guana-
caste vaccination trial of women aged 18–25 years,
Safaeian et al. [10] evaluated cross-reactivity of HC2 on
ThinPrep samples against a highly analytically sensitive
SPF-10 assay. While genotype 66 was not included in
the analysis, 70 and 53 were most frequently involved in
cross-reactivity. Low amounts of viral target input
material and younger age were associated with cross-
reactivity.
In the UK HPV screening trial ARTISTIC, Sargent et
al. found very high proportions of cross-reacting
samples at 20–64 years [11]. Of the 3773 HC2-positive
ThinPrep samples, line blot assay detected only low-risk
genotypes in 11 % (predominantly 53, 66, and 70), and
no genotypes in additional 20 %. In approximately half
of these samples, the signal strength was low, between 1
and 2 RLU/CO. In the Italian HPV screening trial
NTCC, Gillio-Tos et al. [8] genotyped HC2-positive
ThinPrep samples at 25–60 years using GP5+/GP6+
PCR with reverse line blot hybridisation, and, if no
genotypes were found, also restriction fragment length
polymorphism testing and sequencing. Relative cross-
reactivity was 14 % (most frequently because of geno-
types 66, 70, and 53), whereas in 7 % of HC2-positive
samples no HPV DNA was detected. They suggested a
role of the collection medium, and reported a higher
probability of cross-reactivity for ThinPrep than for
Specimen Transport Medium.
Overall, previous studies evaluated cross-reactivity for
HC2 against a variety of genotyping assays, of which
some were research versions and some have been dis-
continued. Several studies were undertaken on frozen
samples stored in various sampling media. Nevertheless,
our data are in line with previous observations. Inde-
pendent evaluations of cross-reactivity for cobas and
APTIMA have not been reported elsewhere, and as such
represent valuable information for decision makers in
choosing assays for screening purposes.
Clinical and technical implications
Of the 175 CIN2/3 in our study, seven (4 %) were associ-
ated with cross-reactivity. The question is whether their
detection and treatment prevented cervical cancer. It could
be hypothesised that these cases were likely regressive.
However, treatment of all high-grade CIN is recommended
in Denmark, so this hypothesis cannot be evaluated using
our data. For HC2, cross-reactivity to genotype 66 played
an important role. Of all 52 single infections with this
genotype, HC2 detected 16 (31 %). APTIMA and cobas
were designed to detect this genotype. Yet, cobas detected
only 31 (60 %), and APTIMA 11 (21 %) single-genotype 66
infections. Nevertheless, given that genotype 66 probably
does not cause cervical cancer [5], the relatively inconsist-
ent detection of this genotype unintentionally improves the
clinical specificity of the two assays.
We propose three scenarios that may have contributed
to cross-reactivity. Firstly, cross-reactivity to low-risk ge-
notypes may have been generated by sequence homology
in the assay amplification target region, whether that
was L1 (cobas), E6/E7 (APTIMA), or whole HPV gen-
ome (HC2). In our data, all three assays showed rather
extensive cross-reactivity to genotype 70. Genotype 70
shares phylogenetic clade (α7) with genotype 18. The lat-
ter is associated with adenocarcinomas and typically
causes lesions characterised by low viral loads compared
to e.g. genotype 16 [30–33]. It seems plausible that the
assays may have been calibrated to detect genotype 18,
but with an unintentional drawback of picking up same-
clade low-risk genotypes. Within this context, the fre-
quent cross-reactivity of HC2 to genotypes 53 and 66,
and occasional cross-reactivity to genotypes 26 and 82,
might be attributable to the fact that they share clades
(α5, α6) with high-risk genotypes 51 and 56.
Secondly, cross-reactivity may have been caused by
detection of non-specific, incomplete amplicons or by
signal amplification probes hybridising to non-target se-
quences. Incomplete or unspecific amplifications would
not hybridise efficiently to the array probes. When using
technologies such as CLART with separate amplification
and detection processes, this would most likely lead to
detection of no genotype.
Thirdly, cross-reactivity may be generated by another
aspect of the assays’ technical designs, in that specific or
non-specific amplifications, otherwise below the positivity
threshold, add up to push the total signal value above the
manufacturer’s cut-off. This additive signal effect might
explain the relatively high likelihood of cross-reactivity ob-
served among younger women and women with abnor-
malities, as they tend to harbour the highest numbers of
multiple infections. Consequently, assays with fewer geno-
type targets per channel or read-out could be speculated
to be more precise from the analytical perspective, making
the case for assays with genotyping beyond that of an indi-
vidual detection of only genotypes 16 and 18.
Conclusions
HC2, cobas and APTIMA all showed cross-reactivity
which seemed to be driven primarily by the assays’
designs. A quarter of all false-positive test results in primary
screening at ≥30 years cross-reacted. To obtain improved
analytical and clinical performance, cross-reactivity should
be addressed by optimising the assays. For now, cross-
reactivity should be addressed in EU tenders, as this
primarily technical shortcoming imposes additional costs
on the screening programmes as well as risking the public’s
view on the effectiveness of cervical screening.
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